Latest Trials Latest NewsFAQ

Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3372689
Diagnostic Test: [18F]LSN3316612

First Posted Date: 2020-05-18

Last Posted Date: 2020-11-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 4

Registration Number: NCT04392271

Locations: 🇺🇸
Institute for Neurodegenerative Disorders, New Haven, Connecticut, United States

A Study of LY3461767 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3461767 - SC
Drug: LY3461767 - IV
Drug: Placebo - SC

First Posted Date: 2020-04-20

Last Posted Date: 2021-02-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT04352114

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
🇺🇸
Covance Dallas, Dallas, Texas, United States
🇸🇬
Lilly Nus Centre for Clin Pharmacology, Singapore, Singapore

A Study of LY3127804 in Participants With COVID-19

Phase 2

Terminated

Conditions: Pneumonia
COVID-19

Interventions: Drug: Placebo
Drug: LY3127804

First Posted Date: 2020-04-13

Last Posted Date: 2021-08-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 95

Registration Number: NCT04342897

Locations: 🇺🇸
Banner Univ Med Ctr Tucson, Tucson, Arizona, United States
🇺🇸
Nuvance Danbury Hospital, Danbury, Connecticut, United States
🇺🇸
Franciscan St. Francis Health, Indianapolis, Indiana, United States

and more 10 locations

A Study of Tirzepatide in Overweight and Very Overweight Participants

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo
Drug: Tirzepatide
Drug: Liraglutide

First Posted Date: 2020-03-17

Last Posted Date: 2024-05-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 114

Registration Number: NCT04311411

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Study of Tirzepatide in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: 14C Tirzepatide

First Posted Date: 2020-03-17

Last Posted Date: 2023-03-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 6

Registration Number: NCT04311424

Locations: 🇬🇧
Covance Clinical Research Ltd, Leeds, West Yorkshire, United Kingdom

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

Phase 4

Completed

Conditions: Migraine

Interventions: Drug: Galcanezumab
Drug: Erenumab

First Posted Date: 2020-03-03

Last Posted Date: 2022-03-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 65

Registration Number: NCT04294147

Locations: 🇺🇸
CMR of Greater New Haven, Waterbury, Connecticut, United States
🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸
Clinical Research Institute LLC, Los Angeles, California, United States

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

Phase 3

Completed

Conditions: Spondyloarthritis

Interventions: Drug: Ixekizumab
Drug: Placebo

First Posted Date: 2020-02-26

Last Posted Date: 2023-04-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 147

Registration Number: NCT04285229

Locations: 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
1st Hospital affiliated to Medical College of Shantou Univer, Shantou, Guangzhou, China
🇨🇳
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China

and more 16 locations

A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY900014
Drug: Insulin Lispro

First Posted Date: 2020-02-19

Last Posted Date: 2021-08-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT04276207

Locations: 🇩🇪
Profil Mainz GmbH & Co. KG, Mainz, Rheinland-Pfalz, Germany

A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3209590
Drug: Insulin Degludec

First Posted Date: 2020-02-19

Last Posted Date: 2020-12-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT04276428

Locations: 🇯🇵
Yokohama Minoru Clinic, Yokohama, Japan
🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Jp-13, Japan
🇯🇵
P-one clinic, Hachioji, Tokyo, Japan

A Study of LY3478045 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3478045
Drug: Placebo
Drug: Atorvastatin

First Posted Date: 2020-02-17

Last Posted Date: 2024-07-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 72

Registration Number: NCT04270370

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy